Movilat (Mucopolysaccharide Polysulfuric Acid Ester, Salicylic Acid)

Mucopolysaccharide Polysulfuric Acid Ester and Salicylic Acid, the active ingredient in Movilat, is a topical dermatological preparation presented as a cutaneous formulation for external use. It is employed to manage certain skin conditions in adult patients, helping to reduce scaling, inflammation and hyperkeratosis. GNH USA supplies Movilat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Movilat is a topical agent used in dermatology to address disorders of keratinisation and inflammation. - Acne vulgaris: helps to unclog pores and reduce inflammatory lesions. - Psoriasis: softens plaques and diminishes scaling. - Plantar or common warts: promotes gradual removal of hyperkeratotic tissue. - Seborrheic dermatitis: alleviates redness and flaking on scalp and face. - Keratosis pilaris: smooths rough skin bumps on arms and thighs.

Topical application of Movilat may be associated with a range of skin reactions.

Common Side Effects: - Mild erythema at the application site. - Dryness or peeling of the treated skin. - Tingling or burning sensation. - Pruritus (itching). - Slight scaling or flaking.

Serious or Rare Side Effects: - Allergic contact dermatitis with vesiculation. - Severe skin ulceration or necrosis. - Systemic hypersensitivity reactions such as angioedema. - Stevens‑Johnson syndrome or toxic epidermal necrolysis (very rare).

Before using Movilat, consider the following safety measures. - Avoid application on open wounds or broken skin: may increase irritation. - Do not use on mucous membranes or near the eyes: risk of severe irritation. - Limit use on large surface areas: excessive absorption can occur. - Pregnant or breastfeeding individuals should consult a healthcare professional before use. - Discontinue if severe irritation or allergic reaction develops and seek medical advice. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Movilat may interact with other topical agents or systemic medications.

Major Interactions (Avoid): - Concurrent use with other keratolytic or exfoliating products (e.g., high‑strength retinoids) can cause excessive skin irritation. - Application over areas treated with topical corticosteroids may alter absorption and increase side‑effects.

Moderate Interactions (Monitor Closely): - Use with occlusive dressings can enhance drug penetration; monitor for signs of irritation. - Systemic retinoids (e.g., isotretinoin) may increase skin sensitivity when combined with Movilat. - Anticoagulant therapy may be affected if large skin areas are treated extensively, due to potential systemic absorption of salicylic acid.